

SCIENTIFIC REPORTS



OPEN

The Effect of rhCygb on CCl₄-Induced Hepatic Fibrogenesis in Rat

Zhen Li*, Wei Wei*, Bohong Chen*, Gaotai Cai, Xin Li, Ping Wang, Jinping Tang & Wenqi Dong

Received: 11 December 2015

Accepted: 08 March 2016

Published: 23 March 2016

This study aims to investigate whether the use of recombinant human cytoglobin (rhCygb) impact on hepatic fibrogenesis caused by CCl₄. SD (n = 150) rats were randomly divided into three groups of normal, CCl₄ model and rhCygb groups. After model establishment, rats in rhCygb groups were administered daily with rhCygb (2 mg/kg, s.c.). Histological lesions were staged according to metavir. Serum parameters including ALT, AST, HA, LN, Col III and Col IV were determined. The liver proteins were separated by 2-DE and identified. As a result, the stage of hepatic damage and liver fibrosis in rhCygb groups were significantly milder than that in CCl₄ model groups. Meanwhile, rhCygb dramatically reversed serum levels of ALT and AST, and also markedly decreased the liver fibrosis markers levels of LN, HA, Col III and Col IV. In 2-DE, 33 proteins among three groups with the same changing tendency in normal and rhCygb treated groups compared with CCl₄ model group were identified. GO analysis showed that several identified proteins involved in oxidative stress pathway. The study provides new insights and data for administration of rhCygb reversing CCl₄-induced liver fibrosis suggesting that rhCygb might be used in the treatment of liver fibrosis.

Liver fibrosis, a pathological process common to chronic liver diseases, is caused by a range of actors, and has a highly deleterious impact on human health. It is well-established that liver fibrosis formation results from an excessive accumulation of extracellular matrix proteins including collagen, a process that occurs in most types of chronic liver disease¹. Liver fibrosis is described in several stages, a normal liver is at stage 0 to 1, stage 2 represents light or minimal fibrosis, stage 3 is severe fibrosis, and stage 4 denotes advanced liver fibrosis resulting in cirrhosis, liver failure, and portal hypertension^{2,3}. Any reversibility of advanced liver fibrosis prior to cirrhosis in patients would be of signal importance.

Because of the urgent clinical need, the development of an anti-fibrotic drug would be an auspicious moment in medical research. Up to now, several candidate treatments with anti-fibrotic properties have been developed, which variously act by blocking inflammatory pathways^{4,5}, inhibiting profibrotic growth factors^{6–8}, modulating epigenetic codes^{9,10}, and interfering with morphogenic pathways^{11,12}, and which have proven efficacy and tolerability in pre-clinical fibrosis models. However, they are not available to treat fibrotic diseases in clinical practice.

The Cygb protein was first discovered in 2001 by proteomic analysis in rat stellate cells, and was initially named stellate cell-activated protein (STAP)¹³. The protein sequence showed that Cygb was hexacoordinate hemoglobin, representing the fourth member of the globin superfamily in mammals¹⁴. Furthermore, immunohistochemical analysis revealed that Cygb was ubiquitously expressed in several organs, such as kidney and pancreas, and localized in fibroblast-like cells¹⁵. Cygb was a 21.4 kDa protein consisting of 190 amino acids and mapped at the 17q25.3 chromosomal segment. Exogenous over-expression of Cygb was soon demonstrated experimentally, both *in vitro* and *in vivo*, to protect hepatic stellate cells (HSC) from oxidative stress and suppress their differentiation to a myofibroblast-like phenotype^{16–18}. Further, it was reported that Cygb had active peroxidase properties, which protected cells against oxidative damage by free radicals^{19–21}. These findings prompted the hypothesis that Cygb could be effective in the prevention or treatment of liver fibrosis. In this study, therefore, we investigate the effect of rhCygb on CCl₄-induced liver fibrosis in rats at various stages of the disease's progression, from mild to severe fibrosis.

Materials and Methods

Preparation of rhCygb. Human cytoglobin cDNA was obtained from HepG2 cells by RT-PCR. A recombinant construct of pET28a-hCyt were transformed into *E. coli* BL21 (DE3). For expression, the bacteria cultures were induced for 4 h using 1 mM isopropyl β-d-thiogalactoside (IPTG) after the culture OD 600 has reached 0.6.

School of Biotechnology, Southern Medical University, Guangzhou, Guangdong Province 510515, P.R. China. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to W.D. (email: dongwq63@263.net)




Figure 1. Schedule for the treatment and experimental tests. Rats were injected with CCl₄ for three different doses to establish mild, medium and severe models at 10, 13 and 15 weeks, 2 times per week. After model was established, rats were treated daily with saline, CCl₄ or rhCygb + CCl₄ for 12 weeks. Rats were sacrificed within 24 h after the last treatment.

The total bacteria cells were collected by centrifugation at 5,000 rpm for 10 min, resuspended in PBS, and broken down by sonication. The rhCygb was purified by sephadex G-25 and affinity chromatography which the monoclonal antibody was prepared by our laboratory. The purified protein was analyzed with SDS-PAGE and identified by mass spectrometry with ABI 4700 Proteomics Analyzer (Applied Biosystems, USA). The yields of rhCygb measured by the software BandScan 5.0 based on SDS-PAGE results. The total antioxidation capacity (T-AOC) of rhCygb was measured spectrophotometrically as described by Tang *et al.*²², using a T-AOC commercial kits (Jiancheng, Nanjing, China) according to the guidelines of the kit.

Ethics statement. All experimental procedures were conducted in conformity with institutional guidelines approved by the Chinese Association of Laboratory Animal Care. All experimental protocols were approved by the Institutional Animal Care and Use Committee in Southern Medical University, Guangzhou, China.

Animals. Sexually mature sprague-dawley (SD) rats ($n = 150$) weighing 180–220 g were obtained from the experimental animal center of Southern Medical University. Care of the animals used in this investigation was conducted according to the guidelines approved by the Chinese Association of Laboratory Animal Care. Rats were housed, five per cage, under constant temperature ($20 \pm 2^\circ\text{C}$) and humidity (70%) with a 12 h light/dark cycle and with free access to chow and water.

Acute toxicity test. BALB/c mice of both sexes, weighing 18–24 g, were obtained from the experimental animal center of Southern Medical University. The acute toxicity of rhCygb was determined *in vivo* using the procedure approved by Chen *et al.*²³. Uninfected mice were peritoneal injected rhCygb at doses of 100 and 500 mg/kg body weight. The animals were monitored for any toxic symptoms or mortality over a 14-day period.

Induction of fibrosis. Three degrees of liver fibrosis were induced by chronic carbon tetrachloride (CCl₄) administration at three different dosage levels:

- Mild model group: 2 ml/kg of 25% CCl₄ in paraffin oil (Sigma Co., Milan, Italy) was administered by subcutaneous injection twice a week (Tuesday and Friday) for 10 weeks;
- Medium model group: treatment in group (a) plus 50% CCl₄ treatment for 3 more weeks;
- Severe model group: treatment in group (b) plus 62.5% CCl₄ for 2 more weeks.

Experiment design. To evaluate the effect of rhCygb on liver fibrosis, 30 rats were used in each of the groups (group a, b, c). A schedule of the treatment is shown in Fig. 1. In each group, followed by CCl₄ treatment, rats were further treated with saline (vehicle group), CCl₄ (model group) or rhCygb (rhCygb group, 2 mg/kg body weight/day, s.c. injection) in combination with CCl₄ for 12 weeks. At the end of the experiments, all rats were sacrificed within 24 h after the last injection.

Chemical analysis. Venous blood samples were collected for serum separation. Samples were stored at -20°C until further analysis. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were measured spectrophotometrically by Olympus/AU 5200 (Konsesyum, Alternative Biomedical Services, Dallas, TX, USA).

Serum liver fibrosis markers hyaluronic acid (HA), laminin (LN), collagen III (Col III) and collagen IV (Col IV) were determined using enzyme-linked immunosorbent assay (ELISA) kits (SIGMA chemical, Corp.).

Pathological studies. In the end of the experiments, rats liver were removed and rinsed with cold saline water. Then liver lesions were fixed, embedded, and stained with Sirius red and hematoxylin-eosin (HE)²⁴. Their evaluation was conducted using a light microscope (Axiphot2, Carl Zeiss) blindly. Fibrosis was scored according to the Metavir scoring system reported by Bedossa *et al.*²⁵. Intralobular degeneration and focal necrosis, portal inflammation and fibrosis were compared across the groups. Three representative images of each histology sample section from each rat were selected randomly and all of the rats were scored.

Protein separation. Five liver samples (approximately 30–40 mg wet) were removed from vehicle group, CCl₄ model group and rhCygb treated group (medium). The samples were then frozen in liquid nitrogen and homogenized with a mortar and pestle. Proteins were prepared in lysis buffer. A total of 120 µg of protein was separated by two-dimensional electrophoresis (2-DE) according to the product manual '2-DE for Proteomics' (Bio-Rad, U.S). After silver staining, each spots were cut out from the gel and digested using trypsin according to the method described by Quattieri *et al.*²⁶.

MS data analysis. Peptide mixtures of each gel spot were dissolved in 0.1% TFA, desalted, and concentrated. The samples were then mixed with the same volume of matrix (CHCA in 30% ACN/0.1% TFA), spotted on a target disk, and allowed to air-dry. Samples were analyzed using a Bruker ultrafleXtreme MALDI-TOF mass spectrometer (Bruker Daltonics, Germany). The protein database search was performed using the MASCOT search engine (<http://www.matrixscience.com/>)²⁷. Mass tolerance was allowed within 150 parts/million (ppm). Peptides matching more than five peptides and with a MASCOT score higher than 60 were considered significant ($p < 0.05$).

Bioinformatics analysis. To identify significantly represented biological themes and functional groups in the protein list (Table 1), the gene ontology (GO) and pathway analysis were performed using the database for annotation, visualization and integrated discovery (DAVID) program (<https://david.ncifcrf.gov/>)²⁷. The GO analysis was used to identify enriched biological themes by the GeneCodis tool (<http://genecodis.cnb.csic.es/>)²⁷. The list of identified proteins was used as the input data when the DAVID default population background was used; We used EASE scores, which modified Fisher's exact test P values < 0.05 and corrected for multiple testing by the Benjamin–Hochberg method.

Modified gene set enrichment analysis (GSEA) was used to assess functional significance at the level of sets of genes as previous described by Li *et al.*²⁸. All of these potential targets were compared with the "c2_all" collection of curated gene sets from the Molecular Signatures Database (GSEA Version 2.0.14), consisting of 1077 gene sets corresponding to BIOCARTA, KEGG and REACTOME biological pathways. The False Discovery Rate (FDR) q value is deemed significant value at < 0.05 .

Statistical analysis. All data were expressed as the mean \pm standard deviation from at least 5 independent experiments. Figures were obtained from at least 5 independent experiments with similar patterns. The biochemical experimental data were analyzed by two-way ANOVA. The Kruskal-Wallis was used for comparisons. Statistical analyses were performed using SPSS software version 19.0 (SPSS Inc, Chicago, USA).

Results

Purity and activity of rhCygb. The purity of rhCygb was 95% by BandScan 5.0 software. The antioxidant activity of rhCygb is 95.58 ± 2.67 U/mg ($p < 0.01$) (supplemental data).

Acute toxicity results. When given as a single dose of 100 and 500 mg/kg, rhCygb produced no signs of acute toxicity in the 14-day period of observation. No death was recorded in the 100- and 500-mg/kg-treated group. All groups of mice exhibited stable temperature values throughout the period of observation.

Developments of CCl₄-induced hepatic fibrosis in rats. All experiments successfully induced fibrosis, as determined by the examination of liver histology and serum biochemistry (Fig. 2A–G). The mortality was 0 in all the experiment groups. According to the results of development of rat liver fibrosis model, rats treated with CCl₄ were sacrificed at 3 different times, 10th week, 13th week and 15th week. At sacrifice, all rats presented marked fibrosis with significant differences in the amount of liver fibrotic tissue among groups. Hepatolobular injury was observed with centrilobular necrosis, balloon cells, and lipids accumulation in 15-weeks-model rats (Fig. 2A). The same results were obtained in an analysis of serum biochemistry (Fig. 2B–G). At the lowest dose (25% CCl₄) for 10 weeks in SD rats, administration of CCl₄ significantly ($p < 0.01$) increased the concentration of AST, ALT, LN, HA, Col III and Col IV in rat serum compared with the levels in the vehicle group (Table 2). Moreover, administration of a higher dose of CCl₄ (50% CCl₄) for a further 3 weeks in group b (medium) resulted in a marked prolongation of toxicity, increasing ($p < 0.01$) serum enzyme values about two-fold except for Col IV. However, there was no significant ($p > 0.05$) difference between the group b (medium) and group c (severe).

Effects of rhCygb on hepatic histoarchitecture. We next evaluated the effect of rhCygb on liver fibrosis following chronic CCl₄ administration. Rats were treated with rhCygb (2 mg/kg/day, s.c.) in combination with CCl₄ (25%, 50% or 62.5%) for 12 weeks. All of the rats survived during the experimental period. The influence of CCl₄ and rhCygb on liver was depicted in Fig. 3, in which liver fibrosis was advanced for 12 more weeks. In this group, fibrotic changes caused by CCl₄ reversed dramatically by rhCygb. As shown in Fig. 3A, the liver appearance of CCl₄-administered rats significantly changed, especially in the medium and severe groups. These

Code	Protein name	Swiss-prot Accession	MW	PI	Protein function
5	Cathepsin D↓	Q6P6T6	45107.04	7.11	Proteolysis; Extracellular matrix
7	Pregnancy-specific beta 1-glycoprotein↓	Q9Z1D6	43326.17	8.73	Pregnancy
9	DnaJ homolog subfamily B member 1↓	Q6TUG0	40754.77	6.26	Serves as a co-chaperone for HSPA5
10	Twinfilin-1↓	Q5RJR2	40293.57	6.65	Regulation of actinphosphorylation; Actin cytoskeleton
11	Haptoglobin↓	P06866	39051.73	6.51	Acute inflammatory response; Acute inflammatory response; Response to hypoxia; Organ regeneration
12	Tubulin beta-4B chain↓	Q6P9T8	50225.16	4.52	Major constituent of microtubules; Structural constituent of cytoskeleton
15	Transitional endoplasmic reticulum ATPase↓	P46462	89976.99	4.89	ER to Golgi vesicle-mediated transport; ATP catabolic process
17	Beta-lactamase-like protein 2↓	Q561R9	32748.81	6.29	Hydrolase activity; Metal ion binding
18	Microtubule-actin cross-linking factor 1↓	D3ZHV2	623207.64	5.07	Wound healing; Epidermal cell migration; Regulation of microtubule-based process
20	GTP-binding protein SAR1b↓	Q5HZY2	22509.55	6.02	ER-Golgi transport; Intracellular protein transport
21	Adenine phosphoribosyltransferase↓	P36972	19761.48	6.52	Adenine salvage; Cellular response to insulin stimulus
22	Protein Sar1a↑	Q6AY18	22498.54	6.68	ER-Golgi transport; Vesicle-mediated transport
25	Long-chain-fatty-acid-CoA ligase 1↑	P18163	79154.6	6.98	Fatty acid metabolism; Beta-oxidation
28	Protein Eea1↑	F1LUA1	162091.42	5.54	Endocytosis; Vesicle fusion
29	Cytochrome P450 2C11↑	P08683	57657.6	7.77	Xenobiotic metabolic process; Monooxygenase; Oxidoreductase
31	Estrogen sulfotransferase↑	P49889	35734.66	5.52	Utilizes 3'-phospho-5'-adenyllyl sulfate (PAPS) as sulfonate donor
32	Biliverdin reductase A↑	P46844	33715.58	6.01	Oxidoreductase; Biliverdin reductase activity
33	Ketohexokinase↑	Q02974	33298.74	6.65	Carbohydrate catabolic process; Response to insulin
34	Protein Inmt↑	D3ZNJ5	29989.04	5.81	Thioether S-methyltransferase activity; Amine N-methyltransferase activity
35	Mitochondrial GTPase 1↑	E9PTB3	36994.54	9.68	Mitochondrial GTPase activity
37	Taste receptor type 1 member 2↑	F8WFI0	62271.78	8.15	Oxidoreductase activity; Acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor
39	Putative L-aspartate dehydrogenase↑	G3V9Z4	30654.77	6.84	NAD biosynthetic process; NADP catabolic process
40	Phenazine biosynthesis-like domain-containing protein↑	Q68G31	31952.24	6.25	Biosynthetic process
41	Carbonic anhydrase 3↑	P14141	29697.82	7.4	Liver response to oxidative stress; Carbonate dehydratase activity
42	Enoyl-CoA hydratase, mitochondrial↑	P14604	31895.34	8.27	Lipid metabolism; Fatty acid beta-oxidation
43	Protein Urad↑	M0RCU5	24634.52	6.44	Carboxy-lyase activity; Allantoin biosynthetic process
44	Glutathione S-transferase Yb-3↑	P08009	25835.08	7.43	Cellular detoxification of nitrogen compound; Xenobiotic catabolic process
45	Peroxiredoxin-2↑	P35704	21941.13	5.28	Removal of superoxide radicals; Response to oxidative stress; Peroxidase activity
46	ATP synthase subunit alpha↑	F1LP05	59889.71	9.72	ATP synthesis coupled proton transport; Lipid metabolic process
47	Glutathione peroxidase 1↑	P04041	22463.37	8.05	Oxidoreductase; Peroxidase; Cell redox homeostasis; Negative regulation of inflammatory; Response to toxic substance
48	Major urinary protein↑	P02761	21008.61	6.13	Negative regulation of lipid storage; Negative regulation of gluconeogenesis; Positive regulation of lipid metabolic process
49	Carboxylesterase 1D↑	P16303	62392.85	6.52	Lipid degradation; Lipid metabolism; acylglycerol catabolic process; Major lipase in white adipose tissue
50	Nucleoporin GLE1↑	Q4KLN4	79954.74	7.65	Poly(A) + mRNA export from nucleus; Protein transport

Table 1. Identification of 33 differentially expressed proteins among normal, CCl₄ model, and rhCygb groups.




Figure 2. Examination of liver histology and serum biochemistry at different stages (10, 13, 15 weeks) in CCl₄ model rats. (A) Representative photomicrographs of HE and Sirius red staining for observing the morphology of fibrosis of rat livers at 10, 13, 15 weeks ($\times 200$); Serum levels of (B) ALT, (C) AST, (D) LN, (E) HA, (F) Col III and (G) Col IV.

groups, after treatment with rhCygb, exhibited a clear and marked improvement in their liver, when compared with those of the CCl₄-administered groups. Photomicrographs of hepatic specimens stained with Sirius red were depicted in Fig. 3B, and the scores of fibrosis variables were presented as medians in Fig. 3C. As shown in the figures, no hepatic fibrosis occurred in the control group, which showed an integrated lobular structure with central venous and hepatic cord radiation. The staging score was 0. Extensive fibrosis and ballooning of hepatocytes were observed in all the CCl₄ model groups. As expected, the high CCl₄ treatment caused fibrous connective tissue proliferation as well as a good deal of collagen fiber formation. Moreover, increased dosages caused even more frequent pseudo lobules to appear in model control groups. The hepatic fibrosis score in the CCl₄ groups

	Group	ALT(U/L)	AST(U/L)	LN(ng/ml)	HA(ng/ml)	Col III(ng/ml)	Col IV(ng/ml)
Mild model	control	24.45 ± 4.02	27.37 ± 6.32	29.76 ± 6.32	112.19 ± 16.66	13.09 ± 2.77	28.28 ± 5.44
	CCl ₄	456.37 ± 95.34 ^a	588.69 ± 115.75 ^a	93.30 ± 11.87 ^a	352.64 ± 33.62 ^a	78.86 ± 10.18 ^a	50.02 ± 5.31 ^a
	CCl ₄ + rhCygb	48.32 ± 7.53 ^c	52.32 ± 5.32 ^c	30.37 ± 3.84 ^c	122.79 ± 19.96 ^c	19.40 ± 5.47 ^c	31.04 ± 5.35 ^c
Medium model	control	33.52 ± 4.3	31.58 ± 6.35	28.45 ± 6.35	107.33 ± 15.26	15.3 ± 3.5	29.35 ± 5.23
	CCl ₄	501.46 ± 98.77 ^a	642.33 ± 98.77 ^a	113.75 ± 12.4 ^a	398.95 ± 48.23 ^a	88.23 ± 15.6 ^a	56.78 ± 7.89 ^a
	CCl ₄ + rhCygb	44.25 ± 7.6 ^c	45.26 ± 7.6 ^c	32.52 ± 7.6 ^c	118.56 ± 25.68 ^c	16.2 ± 3.3 ^c	30.24 ± 5.66 ^c
Severe model	control	35.52 ± 4.3	37.58 ± 6.35	26.45 ± 6.35	97.33 ± 15.26	14.3 ± 3.5	26.35 ± 5.23
	CCl ₄	521.46 ± 98.77 ^a	622.33 ± 98.77 ^a	103.75 ± 12.4 ^a	378.95 ± 48.23 ^a	78.23 ± 14.6 ^a	58.78 ± 7.89 ^a
	CCl ₄ + rhCygb	47.25 ± 7.6 ^c	55.26 ± 7.6 ^c	28.52 ± 7.6 ^c	108.56 ± 25.68 ^c	17.2 ± 3.3 ^c	28.24 ± 5.66 ^c

Table 2. Effects of rhCygb on ALT, AST, LN, HA, Col III and Col IV of CCl₄-induced liver injury SD rats ($\bar{x} \pm SD$, n = 10). ^aCompared with control group $p < 0.01$. ^cCompared with CCl₄ group $p < 0.01$.

increased to 3.40 ± 0.33 , 3.80 ± 0.13 and 3.90 ± 0.1 , respectively. In the rhCygb treated groups, liver had little collagen fiber formation in the peripheral area, and no pseudo lobules. The positive area of Sirius red staining was significantly lower than that of the CCl₄ groups. The scores were 0.27 ± 0.58 (mild group), 0.8 ± 0.19 (medium group) and 0.57 ± 0.16 (severe group), respectively. Similar observations were made in rhCygb groups which evinced statistically significant lower fibrosis scores compared to CCl₄ groups.

Indices of hepatotoxicity: liver marker enzymes. The levels of serum ALT and AST are markers of liver damage. As shown in Table 2, AST and ALT level significantly increased in mild, medium and severe CCl₄ model groups compared with normal control groups, reflecting hepatocellular damage in CCl₄-induced liver fibrosis. Then rhCygb treatment significantly ($p < 0.01$) reversed serum ALT and AST levels in 10 + 12 weeks, 13 + 12 weeks and 15 + 12 weeks groups, to the levels almost equal to vehicle controls.

Effects of rhCygb on levels of LN, HA, Col III and Col IV. In this study, serum LN, HA, Col III and Col IV levels in CCl₄ groups were higher ($p < 0.01$) than controls (Table 2). Compared with the CCl₄ groups, rhCygb also markedly decreased ($p < 0.01$) liver fibrosis marker levels of LN, HA, Col III and Col IV in 10 + 12 weeks, 13 + 12 weeks and 15 + 12 weeks groups.

Differential 2-DE analysis of liver tissue proteins. To study the influence of rhCygb on the proteome of CCl₄-induced fibrotic liver, liver tissues were harvested from the (13 + 12)-weeks-old control group, the CCl₄ model group, and rhCygb treatment group of rats. When examined, the 2-DE gel showed an obvious separation of liver tissue proteins, with 1312 proteins in the vehicle group, 1325 proteins in the CCl₄ model group and 1259 proteins in rhCygb group. Comparing the spots of vehicle to model group or model to rhCygb group by PDquest software for image analysis, a total of 75 protein spots exhibited significant ($p < 0.05$) differences in protein expression between vehicle and model or between model and rhCygb group (supplemental data). These 75 protein spots were grouped into three major patterns (Fig. 4): pattern A: 53 spots differentially expressed between vehicle and CCl₄ group; pattern C: 55 spots differentially expressed between CCl₄ model and rhCygb group; pattern B: 33 spots which overlapped pattern A and pattern C. For example, the expression of cathepsin D in the vehicle group was lower compared to model, while that in rhCygb treated group was also lower. Among the 33 proteins, the expression of 21 proteins were three times higher and that of 12 proteins was three times lower in the vehicle and rhCygb treated groups than in the CCl₄ model group significantly ($p < 0.05$). A total of 33 peptide mass fingerprints (PMFs) were matched and identified by MALDI-TOF-MS and protein database searching, as displayed in Table 1.

Functional annotation of differentially expressed proteins. We analyzed the GO enrichment of these upregulated and downregulated proteins (Table 1). Relevant Protein functions were listed in Table 3. These dysregulated proteins were predicted to be involved in different metabolic processes including the response to stimulus, oxidation-reduction processes, heat-shock protein, the catabolic process and the cytoskeleton.

GSEA (Table 4) revealed that up-regulated genes in rhCygb treated group were significantly enriched in the down-regulated gene set in hepatocellular carcinoma (ranked 1st, $p = 3.33 e^{-8}$, FDR = $2.27 e^{-4}$), or in the genes highly expressed in hepatocellular carcinoma with good survival (ranked 4th, $p = 4.19 e^{-5}$, FDR = $2.77 e^{-2}$). FDR q -value was considered significant at < 0.05 .

Discussion

Much experimental evidence and clinical studies has shown that the physiological functions of Cygb are associated with various diseases, such as cancer²⁹, gastroesophageal reflux disease³⁰, psychomotor retardation epilepsy³¹, and certain neurodegenerative disorders³², especially liver fibrosis. Hence, the aim of the present research was to study the mechanism of liver fibrosis and rhCygb anti-fibrotic action.

Effects of rhCygb on serum markers of fibrosis. CCl₄ proved to be highly useful as an experimental model for the study of liver damage in humans^{33–35}. It is usually used through intraperitoneal injection or oral administration, and with a dosage of 0.2 to 5 ml/kg liver fibrosis is achieved between 4 and 18 weeks^{36,37}. In this study, the mild, medium and severe liver fibrosis rat models were developed through differential doses (25–62.5%) and exposure duration (10–15 weeks) of CCl₄. The results of the present study revealed that




Figure 3. rhCygb treatment attenuates CCl₄-induced rat liver fibrosis. (A) The liver appearance of vehicle control, CCl₄ model and rhCygb groups. (B) Representative photomicrographs of Sirius red staining for observing the morphology of fibrosis of rat livers from different groups ($\times 200$). Black arrows indicate fibrosis. (C) Fibrosis scores (Y axis) of CCl₄ model groups (n = 10) and rhCygb treatment groups (n = 30). Fibrosis scores are based on the percentage of liver area positively stained by Sirius red; **** $p < 0.001$.

continuous and increasing doses of CCl₄ resulted in advanced fibrosis which caused an elevation of levels of serum marker enzymes such as ALT, AST, HA, LN, Col III and Col IV from the mild to the severe model. The serum marker enzymes ALT and AST have previously been reported as important diagnostic factors for hepatic diseases, as they are cytosolic enzymes of the hepatocyte, and increased activity in their circulation reflects cell




Figure 4. Grouping of differentially expressed protein spots. There were 53 differential spots between vehicle and CCl₄ model groups (pattern A), 55 differential between model and rhCygb groups (pattern C), and 33 spots were overlapped between pattern A and pattern C, in which vehicle and rhCygb groups had the same tendency of differential expression compared with ones in model group (pattern B).

Protein function categories	Up-regulation in rhCygb groups	Down-regulation in rhCygb groups
Response to stimulus		Haptoglobin; Adenine phosphoribosyltransferase
Oxidation-reduction process	Peroxioredoxin-2; Glutathione S-transferase Yb-3; Glutathione peroxidase 1; Cytochrome P450 2C11; Biliverdin reductase A; Estrogen sulfotransferase; Taste receptor type 1 member 2; Putative L-aspartate dehydrogenase	
Heat shock protein/chaperones		DnaJ homolog subfamily B member 1; GTP-binding protein SAR1b
Catabolic process	Long-chain-fatty-acid-CoA ligase 1; Enoyl-CoA hydratase, mitochondrial; Carboxylesterase 1D; ATP synthase subunit alpha; Major urinary protein; Protein Inmt; Phenazine biosynthesis-like domain-containing protein; Ketohehexokinase	
Cytoskeleton		Tubulin beta-4B chain; Microtubule-actin cross-linking factor 1; Cathepsin D

Table 3. Identification of the differential expressed proteins through the use of GO analysis.

damage and leakage³⁸. High ALT and AST levels are associated with a higher risk of fibrosis progression. The present study demonstrates that rhCygb can reduce heightened ALT and AST, indicating that they can promote the repair of injured liver cell.

In addition, HA, LN, Col III and Col IV have been found to be ideal serum markers of hepatic fibrosis, which play an important role in detecting the degree of hepatic fibrosis³⁹. In the present study, CCl₄ model groups increased markedly compared with normal groups. However, after the treatment of rhCygb (therapy but not removing CCl₄), we detected that the serum contents of HA, LN, Col III and Col IV decreased to the level of normal groups. This may be the basic mechanism of rhCygb reversing rat hepatic fibrosis.

Gene Set Name	Description	Genes in Overlap	p-value	FDR q-value
SHETH LIVER CANCER VS TXNIP LOSS PAM4	Cluster PAM4: genes down-regulated in hepatocellular carcinoma (HCC) vs normal liver tissue from mice deficient for TXNIP [GeneID = 10628].	5	3.33 e ⁻⁸	1.13 e ⁻⁴
AMBROSINI FLAVOPIRIDOL TREATMENT TP53	Genes down-regulated by flavopiridol [PubChem = 5287969] in the HCT116 cells (colon cancer) depending on their TP53 [GeneID = 7157] status: wild-type vs loss of the gene's function (LOF).	3	2.57 e ⁻⁵	2.03 e ⁻²
ACEVEDO_LIVER_CANCER_DN	Genes down-regulated in hepatocellular carcinoma (HCC) compared to normal liver samples	4	3.97 e ⁻⁵	2.03 e ⁻²
LEE LIVER CANCER SURVIVAL UP	Genes highly expressed in hepatocellular carcinoma with good survival.	3	8.05 e ⁻⁵	3.39 e ⁻²
HOUSTIS ROS	Genes known to modulate ROS or whose expression changes in response to ROS	2	8.98 e ⁻⁵	3.39 e ⁻²
VARELA ZMPSTE24 TARGETS DN	Top genes down-regulated in liver tissue from mice with knockout of ZMPSTE24 [GeneID = 10269].	2	8.98 e ⁻⁵	3.39 e ⁻²
OHGUCHI LIVER HNF4A TARGETS UP	Genes up-regulated in liver samples of liver-specific knockout of HNF4A [GeneID = 3172]	2	1.21 e ⁻⁴	4.1 e ⁻²

Table 4. GSEA result for the up-regulated genes in rhCygb treated groups vs CCl₄ model group.

Effects of rhCygb on stages of fibrosis. In response to liver injury induced by whatever cause, collagen and matrix proteins are produced in much higher quantities by activated hepatic stellate cells, which ultimately leads to liver fibrosis⁴⁰. Fibrosis is evaluated by using Sirius red staining and scored using the fibrosis staging system (the Metavir score). The Metavir system scores necroinflammatory activity from 0 to 3 and fibrosis from 0 to 4²⁵. In this study, evaluation of staging revealed a score of 4 in different cases in CCl₄ model groups: 70% in the mild group, 80% in the medium group and 90% in the severe group. However, score 4 didn't show up in any of the rhCygb treated groups. In time, score 0 was present in 24 rats in the mild group, 18 rats in the medium group, and 19 rats in the severe group. These data are in solid agreement with the activities of serum biomarkers. Interestingly, the stages of fibrosis were previously believed to be progressive and largely irreversible. There is now mounting experimental and clinical evidence suggesting that liver fibrosis can regress in all chronic liver diseases by withdrawing the cause of liver injury or by treatment of the disease^{41,42}. Our paper also obtains that CCl₄-induced rat liver fibrosis was markedly reversed by administration of rhCygb. He *et al.* reported the similar findings in their use of rhCygb in the thioacetamide (TAA)-induced rat liver fibrosis model⁴³.

Effects of rhCygb on protein species. We systematically analyzed the effect of rhCygb on liver proteome in the CCl₄-induced rat model. Thirty-three differentially expressed proteins appeared among the three groups, with the same alteration profile in the vehicle and rhCygb treated groups compared with the CCl₄ model group, identified through comparative proteomics. Functional annotation analysis showed several identified proteins involved in oxidative stress pathways, such as the response to chemical stimuli, oxidative-reduction, and xenobiotic metabolic processes. Oxidative stress is thought to be a critical factor in the development of CCl₄-induced liver fibrosis⁴⁴. Previous studies have reported the effects of rhCygb on the levels of oxidative stress biomarkers and anti-oxidative capacity⁴⁵. The current results show that rhCygb regulates antioxidant enzymes such as peroxiredoxin-2, glutathione S-transferase, glutathione peroxidase 1, cytochrome P450 2C11, biliverdin reductase A, estrogen sulfotransferase, and taste receptor type 1 member 2. One of these proteins, P450 2C11, an enzyme that was increased by rhCygb, plays an important role in the deactivation of estrogens via 16 α -hydroxylation and catechol formation. It is particularly active in relation to the development of fatty change, hepatic fibrosis, portal hypertension, and cirrhosis⁴⁶. Earlier studies have shown that P450 2C11 activity in rat models of experimental liver disease including hepatic cirrhosis is produced by CCl₄⁴⁷. The present study also demonstrated that the level of protein P450 2C11 in the liver decreased significantly in this model of liver fibrosis at the 25-week time point. In addition, we also found that enzymes involved in fatty acid β -oxidation (Long-chain-fatty-acid-CoA ligase 1, Enoyl-CoA hydratase, Carboxylesterase 1D and ATP synthase sub-unit alpha) were down-regulated in CCl₄ model group, whereas in the rhCygb-treated group they were up-regulated (as they were in the vehicle group). These findings show that impairment of fatty acid oxidation may contribute to hepatic fibrosis.

In summary, the results of the present study demonstrate that in addition to the effect of reversing liver fibrosis, rhCygb could reduce the serum levels of ALT, AST, HA, LN, Col III and Col IV, indicating that it has definite effects in reversing the formation of liver fibrosis in the course of chronic hepatitis. The differentially expressed proteins have several groups of biological functions, especially relating to oxidative stress, which are helpful in revealing the underlying mechanisms of rhCygb action against liver fibrosis. rhCygb could be a novel candidate drug in combating liver fibrosis.

References

- Eng, F. J. & Friedman, S. L. Fibrogenesis, I. New insights into hepatic stellate cell activation: the simple becomes complex. *Am J Physiol* **279**, G7–G11 (2000).
- Marcellin, P., Asselah, T. & Boyer, N. Fibrosis and disease progression in hepatitis C. *Hepatology* **36**, 47–56 (2002).
- Ghany, M. G. *et al.* Progression of fibrosis in early stages of chronic hepatitis C. *Hepatology* **32**, 496A (2000).
- Riemekasten, G. *et al.* Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. *Ann Rheum Dis* **70**, 530–536 (2011).
- Rankin, A. L. *et al.* IL-33 induces IL-13-dependent cutaneous fibrosis. *J Immunol* **184**, 1526–1535 (2010).

6. Akhmetshina, A. *et al.* Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. *FASEB J* **22**, 2214–2222 (2008).
7. Akhmetshina, A. *et al.* Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. *Arthritis Rheum* **60**, 219–224 (2009).
8. Tashkin, D. P. *et al.* Cyclophosphamide versus placebo in scleroderma lung disease. *N Engl J Med* **354**, 2655–2666 (2006).
9. Huber, L. C. *et al.* Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of -induced skin fibrosis. *Arthritis Rheum* **56**, 2755–2764 (2007).
10. Venalis, P. *et al.* Lack of inhibitory effects of the anti-fibrotic drug imatinib on endothelial cell functions *in vitro* and *in vivo*. *J Cell Mol Med* **13**, 4185–4191 (2009).
11. Bergmann, C. *et al.* Inhibition of glycogen synthase kinase 3 beta induces dermal fibrosis by activation of the canonical Wnt pathway. *Ann Rheum Dis* **70**, 2191–2198 (2011).
12. Horn, A. *et al.* Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. *Arthritis Rheum* **64**, 2724–2733 (2012).
13. Kawada, N. *et al.* Characterization of a stellate cell activation associated protein (STAP) with peroxidase activity found in rat hepatic stellate cells. *J Biol Chem* **276**, 25318–25323 (2001).
14. Fago, A. *et al.* Allosteric regulation and temperature dependence of oxygen binding in human neuroglobin and cytoglobin. Molecular mechanisms and physiological significance. *J Biol Chem* **279**, 44417–44426 (2004).
15. Burmester, T. *et al.* Cytoglobin: a novel globin type ubiquitously expressed in vertebrate tissues. *Mol Biol Evol* **19**, 416–421 (2002).
16. Hodges, N. J. *et al.* Cellular protection from oxidative DNA damage by over-expression of the novel globin cytoglobin *in vitro*. *Mutagenesis* **23**, 293–298 (2008).
17. Fordel, E. *et al.* Neuroglobin and cytoglobin expression in mice. *FEBS J* **274**, 1312–1317 (2007).
18. Xu, R. *et al.* Cytoglobin over expression protects against damage-induced fibrosis. *Mol Ther* **13**, 1093–1100 (2006).
19. Trent 3rd, J. T. & Hargrove, M. S. An ubiquitously expressed human hexaco-ordinate hemoglobin. *J Biol Chem* **277**, 19538–19545 (2002).
20. Li, H. *et al.* Characterization of the mechanism and magnitude of cytoglobin mediated nitrite reduction and nitric oxide generation under anaerobic conditions. *J Biol Chem* **287**, 36623–36633 (2012).
21. Gardner, A. M., Cook, M. R. & Gardner, P. R. Nitric-oxide dioxygenase function of human cytoglobin with cellular reductants and in rat hepatocytes. *J Biol Chem* **285**, 23850–23857 (2010).
22. Tang, R. *et al.* Mechanisms of selenium inhibition of cell apoptosis induced by oxysterols in rat vascular smooth muscle cells. *Arch Biochem Biophys* **441**, 16–24 (2005).
23. Chen, K. W. & Ho, W. S. Anti-oxidative and hepatoprotective effects of lithospermic acid against carbon tetrachloride-induced liver oxidative damage *in vitro* and *in vivo*. *Oncol Rep* **34**, 673–680 (2015).
24. Ding, H. *et al.* Assessment of liver fibrosis: the relationship between point shear wave elastography and quantitative histological analysis. *J Gastroenterol Hepatol* **30**, 553–558 (2015).
25. Bedossa, P. & Poynard, T. The METAVIR cooperative study group. An algorithm for the grading of activity in chronic hepatitis C. *Hepatology* **24**, 289–293 (1996).
26. Qualtieri, A. *et al.* Two-dimensional gel electrophoresis of peripheral nerve proteins: optimized sample preparation. *J Neurosci Methods* **159**, 125–133 (2007).
27. Nagasawa, K. *et al.* Significant modulation of the hepatic proteome induced by exposure to low temperature in *Xenopus laevis*. *Biol Open* **2**, 1057–1069 (2013).
28. Li, J. *et al.* Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenström macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy. *Blood* **115**, 3580–3588 (2010).
29. Xinarianos, G. *et al.* Frequent genetic and epigenetic abnormalities contribute to the deregulation of cytoglobin in non-small cell lung cancer. *Hum Mol Genet* **15**, 2038–2044 (2006).
30. McDonald, F. E. *et al.* Down-regulation of the cytoglobin gene, located on 17q25, in tylosis with oesophageal cancer (TOC): evidence for trans-allele repression. *Hum Mol Genet* **15**, 1271–1277 (2006).
31. Hedley-Whyte, E. T. *et al.* Hyaline protoplasmic astrocytopathy of neocortex. *J Neuropathol Exp Neurol* **68**, 136–147 (2009).
32. Powers, J. M. p53-mediated apoptosis, neuroglobin over expression and globin deposits in a patient with hereditary ferritinopathy. *J Neuropathol Exp Neurol* **65**, 716–721 (2006).
33. Guillaume, M. *et al.* Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl₄-cirrhotic rats. *J Hepatol* **58**, 240–246 (2013).
34. Kataoka, T. *et al.* Comparative study on the inhibitory effects of α -tocopherol and radon on carbon tetrachloride-induced renal damage. *Ren Fail* **34**, 1181–1187 (2012).
35. Nowatzky, J. *et al.* Inactivated Orf virus (Parapoxvirus ovis) elicits antifibrotic activity in models of liver fibrosis. *Hepatology Res* **43**, 535–546 (2013).
36. Saba, A. B., Onakoya, O. M. & Oyagbemi, A. A. Hepatoprotective and *in vivo* antioxidant activities of ethanolic extract of whole fruit of *Lagenariabreviflora*. *J Basic Clin Physiol Pharmacol* **23**, 27–32 (2012).
37. Marques, T. G. *et al.* Review of experimental models for inducing hepatic cirrhosis by bile duct ligation and carbon tetrachloride injection. *Acta Cir Bras* **27**, 589–594 (2012).
38. Martinot-Peignoux, M. *et al.* Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. *Hepatology* **34**, 1000–1005 (2001).
39. Vaillant, B. *et al.* Regulation of hepatic fibrosis and extracellular matrix genes by the response: new insight into the role of tissue inhibitors of matrix metalloproteinases. *J Immunol* **167**, 7017–7026 (2001).
40. Beaussier, M. *et al.* Prominent contribution of portal mesenchymal cells to liver fibrosis in ischemic and obstructive cholestatic injuries. *Lab Invest* **87**, 292–303 (2007).
41. Liaw, Y. F. Reversal of cirrhosis: an achievable goal of hepatitis B antiviral therapy. *J Hepatol* **59**, 880–881 (2013).
42. Hui, C. K. *et al.* Hong Kong Liver Fibrosis Study Group. Serum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B. *J Hepatol* **47**, 191–202 (2007).
43. He, X. *et al.* Cytoglobin exhibits anti-fibrosis activity on liver *in vivo* and *in vitro*. *Protein J* **30**, 437–446 (2011).
44. Gutiérrez, R. *et al.* Oxidative stress modulation by *Rosmarinus officinalis* in CCl₄-induced liver cirrhosis. *Phytother Res* **24**, 595–601 (2010).
45. Chakraborty, S., John, R. & Nag, A. Cytoglobin in tumor hypoxia: novel insights into cancer suppression. *Tumour Biol* **35**, 6207–6219 (2014).
46. Wójcikowski, J., Haduch, A. & Daniel, W. A. Effect of antidepressant drugs on cytochrome P450C11 (CYP2C11) in rat liver. *Pharmacol Rep* **65**, 1247–1255 (2013).
47. Nomura, A., Sakurai, E. & Hikichi, N. Effect of carbon tetrachloride-induced hepatic injury on stereoselective N-demethylation of chlorpheniramine by rat hepatic cytochrome P450 2C11 isozyme. *YakugakuZasshi* **118**, 317–323 (1998).

Acknowledgements

This work was supported by the National Natural Science Foundation of China (No. 81200394), Guangdong Province Science and Technology Plan Project (No. 2010B031500012, No. 2013A022100027) and Guangzhou science and technology project (No. 201510010104).

Author Contributions

L.Z., W.W. and C.B. performed the majority of experiments; C.G., L.X., W.P. and T.J. provided vital analysis and interpretation of data and were also involved in editing the manuscript; D.W. designed the study and wrote the manuscript.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Li, Z. *et al.* The Effect of rhCygb on CCl₄-Induced Hepatic Fibrogenesis in Rat. *Sci. Rep.* **6**, 23508; doi: 10.1038/srep23508 (2016).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>